Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation - Archive ouverte HAL Access content directly
Journal Articles Cancer Year : 2021

Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

, , , (1) , , , , , , , , , , , , , (2) , , , , , , ,
1
2
Giorgia Battipaglia
Myriam Labopin
Rose‐marie Hamladji
  • Function : Author
Patrice Chevallier
Eolia Brissot
  • Function : Author
Armin Gerbitz
  • Function : Author
Gerard Socié
Boris Afanasyev
  • Function : Author
Fabio Ciceri
Ellen Meijer
  • Function : Author
Yener Koc
  • Function : Author
Jan Cornelissen
  • Function : Author
Anne Huynh
  • Function : Author
Hakan Ozdogu
  • Function : Author
Johan Maertens
Hélène Labussière‐wallet
  • Function : Author
Annalisa Ruggeri
Mahmoud Aljurf
  • Function : Author
Ali Bazarbachi
Bipin Savani
Arnon Nagler
Mohamad Mohty

Abstract

Background: Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Addition of antithymocyte globulin (ATG) or post-transplantation cyclophosphamide (PTCY) to standard immunosuppressive agents reduces GVHD in different donor settings. Methods: We compared the outcomes of adults with acute myeloid leukemia undergoing allo-HSCT from HLA-identical sibling donors after the use of PTCY (n = 197) or ATG (n = 1913). Results: Patients in the PTCY group were younger than those in the ATG group (median age, 47 vs 54 years; P < .01). Peripheral blood was the most frequently used stem cell source, being significantly more frequent in the ATG group than in the PTCY group (95% vs 70% P < .01). The conditioning regimen was more frequently myeloablative in the PTCY group than in the ATG group (59% vs 48%; P < .01). Time to neutrophil engraftment was shorter in the ATG group than in the PTCY group (17 vs 20 days; P < .01). No differences were observed according to the other transplantation outcomes, except for chronic GVHD of all grades and extensive chronic GVHD at 2 years, which were significantly lower in the ATG group compared with the PTCY group (P < .02). Conclusion: PTCY is feasible in an HLA-identical sibling setting, and despite similar outcomes, ATG may be associated with lower incidence of chronic GVHD.
Not file

Dates and versions

hal-03152844 , version 1 (25-02-2021)

Identifiers

Cite

Giorgia Battipaglia, Myriam Labopin, Rose‐marie Hamladji, Didier Blaise, Patrice Chevallier, et al.. Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2021, 127 (2), pp.209-218. ⟨10.1002/cncr.33255⟩. ⟨hal-03152844⟩

Collections

CNRS UNIV-AMU CRCM
24 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More